Endocannabinoid Enzyme Inhibition Delayed Neuropathy Without Permanently Preventing It
Two FAAH inhibitors suppressed pain-related behavior during treatment, but neuropathy emerged after restricted preventive dosing stopped. Delaying an endpoint was not the same as permanently preventing the condition.
Indirect cannabinoid-system modulation
Researchers compared brain-permeant URB597, peripherally restricted URB937 and a direct synthetic agonist in paclitaxel-treated mice. FAAH inhibition alters endogenous lipid signaling; it is not equivalent to administering THC.
Positive and negative findings coexisted
Both inhibitors retained efficacy during the studied repeated regimens without the assessed tolerance or antagonist-precipitated dependence signs. However, stopping the preventive course did not permanently stop neuropathy. Separate tumor-cell assays suggested favorable combinations with paclitaxel, but those were in-vitro viability results.
Clinical claims need separate evidence
An animal hypersensitivity measure is not patient-reported pain, and reduced tumor-cell viability is not demonstrated cancer treatment in people. The findings did not establish that cannabis prevents chemotherapy injury or improves cancer survival. They support distinguishing sustained symptom suppression, disease modification and tumor-cell pharmacology before combining several favorable laboratory results into one clinical promise.
Related analysis: Cannabis Tolerance Claims: Questions to Ask Before Relying on Expert Testimony.
Primary research
Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro. Pharmacological research (2019). DOI: 10.1016/j.phrs.2019.02.002.
